http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019237688-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb7bcd6144acb6e427ecc6d3ca4ba85c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e14dcbfc767bc6ee4c17abb423ffe62c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e24b8afe0117f44719f4a7fe478978e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6c3458b2b262cd9e9ff7d54eb8fa616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4364b33124e328ea9726626cffb8bc2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cef8622e537b0a13f45978c35b617316 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7b7af51a753e0493edb07834792dab2 |
| publicationDate | 2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019237688-A1 |
| titleOfInvention | Application of niemann-pick c1 protein in diagnosis and treatment of cancer |
| abstract | Disclosed in the present invention is a Niemann-Pick C1 protein (NPC1) and new use of a substance inhibiting NPC1 gene expression and/or protein activity, selected from at least one of the following: (a) used for preparing a kit for diagnosis of liver cancer; (b) used for preparing a kit for prognosis of liver cancer; (c) used for preparing a companion diagnostic kit for treatment of liver cancer; (d) used for preparing a drug for preventing and/or treating a cancer; (e) used for preparing a drug for preventing and/or treating diffusion transfer of a cancer; (f) used for preparing a drug for promoting apoptosis of cancer cells; (g) used for preparing a drug for inhibiting cancer cells from developing into a cancer; and (h) used for preparing a drug for inhibiting in-vitro proliferation of cancer cells. Experiments prove that NPC1 is obviously highly expressed in a liver cancer tissue and a serum, the high abundance of NPC1 prompts that the prognosis of a liver cancer patient is poor, and NPC1 can be used as a marker of early diagnosis, prognosis, or diagnosis and treatment guidance of tumors, in particular, liver cancer, independently or in combination with other proteins. An NPC1 inhibitor can be used as a candidate drug target of tumors, in particular, liver cancer. |
| priorityDate | 2017-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 179.